{"schema_version":"1","generated_at":"2026-11-20T16:34:48.122Z","data_as_of":null,"url":"https://www.findmykol.com/kol/benjamin-esparaz","json_url":"https://www.findmykol.com/kol/benjamin-esparaz/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"benjamin-esparaz","name":"Benjamin Esparaz","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Heartland Cancer Research","institution_url":"https://www.findmykol.com/institution/heartland-cancer-research","city":"Decatur","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Benjamin Esparaz is an Oncology physician affiliated with Heartland Cancer Research. OpenAlex indexes 47 publications with 895 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":47,"cited_by_count":895,"h_index":10,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":55,"program_years":{"first":2021,"last":null},"rows_total":109,"shown":3,"withheld":106,"rows":[{"payer":"Astellas Pharma US Inc","program_year":2025,"amount_usd":23.97,"payment_count":1},{"payer":"Corcept Therapeutics","program_year":2025,"amount_usd":23.1,"payment_count":1},{"payer":"EMD Serono, Inc.","program_year":2025,"amount_usd":20.7,"payment_count":1}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":9,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":40.6,"classes_total":3,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":39.8,"drugs":[{"name":"Palonosetron hcl","share_pct":50.4},{"name":"Ondansetron hydrochloride","share_pct":46},{"name":"Ondansetron Hcl","share_pct":3.6}],"max_beneficiaries":31},{"class":"Corticosteroid","setting":"prescribed","share_pct":0.5,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":14}]},{"area":"Sensory organs","share_pct":40.4,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"mixed","share_pct":40.1,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":97.9},{"name":"Dexamethasone","share_pct":2.1}],"max_beneficiaries":38},{"class":"Aminoglycoside Antibacterial","setting":"prescribed","share_pct":0.3,"drugs":[{"name":"Gentamicin Sulfate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":8,"classes_total":5,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":4.6,"drugs":[{"name":"Anastrozole","share_pct":92.9},{"name":"Letrozole","share_pct":7.1}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":2.2,"drugs":[{"name":"Imbruvica","share_pct":64.4},{"name":"Ibrance","share_pct":21.8},{"name":"Everolimus","share_pct":13.9}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":99.7,"facility_pct":0.3},"source":"medicare"},"publications":{"total":47,"shown":5,"withheld":42,"matched_by":"OpenAlex author record","recent":[{"title":"Longitudinal physical activity patterns and patient-reported cognitive function among patients with lymphoma receiving chemotherapy in a nationwide prospective cohort.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.12111","status":"verified"},{"title":"Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-24-01710","status":"verified"},{"title":"NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.17_suppl.lba509","status":"verified"},{"title":"Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia","year":2025,"journal":"BJC Reports","source_url":"https://doi.org/10.1038/s44276-025-00176-9","status":"verified"},{"title":"Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy","year":2025,"journal":"JNCI Cancer Spectrum","source_url":"https://doi.org/10.1093/jncics/pkaf105","status":"verified"}],"source":"works"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":106,"publications":42}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}